CJPR

Previous Articles     Next Articles

  

  • Online:2020-04-01 Published:2020-04-17

胆道恶性肿瘤药物治疗进展

吕文杰刘颖斌   

  1. 上海交通大学医学院附属新华医院普外科,上海 200092

Abstract: New pharmacological treatment in biliary tract cancers             LV Wen-jie,LIU Ying-bin. Department of General Surgery,Xinhua Hospital,Affiliated to Shanghai Jiao Tong University,School of Medicine,Shanghai 200092,China
Corresponding author:LIU Ying-bin,E-mail:laoniulyb@163.com
Abstract    Biliary tract cancers (BTCs),including cholangiocarcinoma and gallbladder cancer,are poor-prognosis and low-incidence cancers. A minority of patients presents with resectable disease;however,relapse rates are high;benefit from adjuvant pharmacological treatment has been suggested. High level evidence-based medicine evidence has confirmed the effectiveness of first-line chemotherapy for advanced BTC; meanwhile, the development of targeted drugs has brought new hope for the drug treatment of BTC, and immunotherapy has been constantly explored. BTC will probably be controlled and the prognosis of patients will be improved.

Key words: biliary tract cancer, chemotherapy, molecular targeted therapy, immunotherapy

摘要: 胆道恶性肿瘤(BTC)包括肝内外胆管癌及胆囊癌,发病率低,预后较差。少数病人可获得手术切除,然而术后复发率仍较高。近年的研究报告显示,BTC病人可从药物的辅助治疗中有所获益。高级别的循证医学证据已证实对进展期BTC进行一线化疗的有效性;同时,靶向药物的推陈出新使BTC的药物治疗出现了新的希望,免疫治疗也在不断进行探索。BTC将有可能得到控制,病人预后得以改善。

关键词: 胆道恶性肿瘤, 化疗, 靶向治疗, 免疫治疗